New Foam Treatment Effective for Moderate to Severe Acne



A recent study found that a topical minocycline foam, FMX 101 4%, was safe and effective for the treatment of moderate to severe acne.

The 2 identical phase 3 studies included a total of 961 participants with moderate to severe acne vulgaris. Participants were randomized to once-daily FMX 101 4% foam or vehicle for 12 weeks. Changes in inflammatory lesion count from baseline to week 12 and treatment success rate, defined as Investigator’s Global Assessment score of 0 or 1 (clear or almost clear), at week 12 were assessed as the primary endpoints.  

FDA Approves New Topical for Acne
Adherence to Acne Medication Hindered by Costs
Acne Inflates Depression Risk by 63%

In both studies participants treated with FMX 101 4% foam experienced significantly greater reductions in inflammatory lesions compared with those treated with vehicle. Additionally, noninflammatory lesion count was significantly lower among participants treated with FMX 101 4% foam compared with vehicle. The pooled analyses of both studies showed statistical significance on both endpoints.  

Skin-related adverse events were reported in less than 1% of participants who received FMX 101 4% foam.

“FMX101 4% topical minocycline foam appears to be a safe and efficacious treatment for moderate to severe acne,” the researchers concluded.


Gold LS, Dhawan S, Weiss J, Draelos ZD, Ellman, H, Stuart IA. A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: results of two randomized, double-blind, phase 3 studies [published online August 27, 2018]. J Am Acad Dermatol. doi:10.1016/j.jaad.2018.08.020